Back to results
US 11,203,565 B2Granted
Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used
AssigneesHiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
InventorsTomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.
Claims18
A compound represented by Formula (I):
- wherein
- m represents an integer of 1 to 3, and n represents an integer of 0 to 2, with the proviso that 1≤m+n≤3;
- R1 represents a hydrogen atom, a hydrocarbon group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), or an amino group optionally having a substituent(s);
- R2 represents a polycyclic aryl group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), an aryloxy group optionally having a substituent(s), a phenyl group having a substituent(s), an aralkyl group having a substituent(s), or a group represented by the following Formula (II):
- wherein Ring A and Ring B each represent a monocyclic or polycyclic aryl group or heterocyclic group optionally having a substituent(s);
- R4 represents a single bond, a C1-3 alkylene group optionally having a substituent(s), a C2-3 alkenylene group optionally having a substituent(s), or a divalent oxy group;
- and the Ring A, Ring B, or R4 moiety is linked to X;
- R3 represents 0 to 7 substituent(s) linked to the naphthyl group, each of which substituent(s) is the same or different and has 1 to 10 atoms;
- and
- X represents:
- (i) a single bond;
- (ii) a C1-6 alkylene group optionally having a substituent(s);
- (iii) a C2-6 alkenylene group optionally having a substituent(s);
- (iv) an —R5—NH— group or an —NH—R5— group, wherein R5 represents a C1-5 alkylene group optionally having a substituent(s), or a C2-5 alkenylene group optionally having a substituent(s);
- or
- (v) a secondary or tertiary amino group;
- or a salt thereof.
14 more elements
A method for treating an inflammatory disease accompanied by fibrosis, wherein said method comprises administering to a subject in need thereof a therapeutic amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:
- wherein
- m represents an integer of 0 to 3, and n represents an integer of 0 to 2, with the proviso that 1<m+n<3;
- R1 represents a hydrogen atom, a hydrocarbon group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), or an amino group optionally having a substituent(s);
- R2 represents a polycyclic aryl group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), an aryloxy group optionally having a substituent(s), a phenyl group having a substituent(s), an aralkyl group having a substituent(s), or a group represented by the following Formula (II):
- wherein Ring A and Ring B each represent a monocyclic or polycyclic aryl group or heterocyclic group optionally having a substituent(s);
- R4 represents a single bond, a C1-3 alkylene group optionally having a substituent(s), a C2-3 alkenylene group optionally having a substituent(s), or a divalent oxy group;
- and the Ring A, Ring B, or R4 moiety is linked to X;
- R3 represents 0 to 7 substituent(s) linked to the naphthyl group, each of which substituent(s) is the same or different and has 1 to 10 atoms;
- and
- X represents:
- (i) a single bond;
- (ii) a C1-6 alkylene group optionally having a substituent(s);
- (iii) a C2-6 alkenylene group optionally having a substituent(s);
- (iv) an —R5—NH— group or an —NH—R5— group, wherein R5 represents a C1-5 alkylene group optionally having a substituent(s), or a C2-5 alkenylene group optionally having a substituent(s);
- or
- (v) a secondary or tertiary amino group.
13 more elements
A method for treating colon cancer, wherein said method comprises administering to a subject in need thereof a therapeutic amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:
- wherein
- m represents an integer of 0 to 3, and n represents an integer of 0 to 2, with the proviso that 1<m+n<3;
- R1 represents a hydrogen atom, a hydrocarbon group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), or an amino group optionally having a substituent(s);
- R2 represents a polycyclic aryl group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), an aryloxy group optionally having a substituent(s), a phenyl group having a substituent(s), an aralkyl group having a substituent(s), or a group represented by the following Formula (II):
- wherein Ring A and Ring B each represent a monocyclic or polycyclic aryl group or heterocyclic group optionally having a substituent(s);
- R4 represents a single bond, a C1-3 alkylene group optionally having a substituent(s), a C2-3 alkenylene group optionally having a substituent(s), or a divalent oxy group;
- and the Ring A, Ring B, or R4 moiety is linked to X;
- R3 represents 0 to 7 substituent(s) linked to the naphthyl group, each of which substituent(s) is the same or different and has 1 to 10 atoms;
- and
- X represents:
- (i) a single bond;
- (ii) a C1-6 alkylene group optionally having a substituent(s);
- (iii) a C2-6 alkenylene group optionally having a substituent(s);
- (iv) an —R5—NH— group or an —NH—R5— group, wherein R5 represents a C1-5 alkylene group optionally having a substituent(s), or a C2-5 alkenylene group optionally having a substituent(s);
- or
- (v) a secondary or tertiary amino group.
13 more elements
A method for preparing a pharmaceutical for the treatment of an inflammatory disease accompanied by fibrosis, wherein said method comprises combining a pharmaceutically acceptable carrier and a therapeutic amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:
- wherein
- m represents an integer of 0 to 3, and n represents an integer of 0 to 2, with the proviso that 1<m+n<3;
- R1 represents a hydrogen atom, a hydrocarbon group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), or an amino group optionally having a substituent(s);
- R2 represents a polycyclic aryl group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), an aryloxy group optionally having a substituent(s), a phenyl group having a substituent(s), an aralkyl group having a substituent(s), or a group represented by the following Formula (II):
- wherein Ring A and Ring B each represent a monocyclic or polycyclic aryl group or heterocyclic group optionally having a substituent(s);
- R4 represents a single bond, a C1-3 alkylene group optionally having a substituent(s), a C2-3 alkenylene group optionally having a substituent(s), or a divalent oxy group;
- and the Ring A, Ring B, or R4 moiety is linked to X;
- R3 represents 0 to 7 substituent(s) linked to the naphthyl group, each of which substituent(s) is the same or different and has 1 to 10 atoms;
- and
- X represents:
- (i) a single bond;
- (ii) a C1-6 alkylene group optionally having a substituent(s);
- (iii) a C2-6 alkenylene group optionally having a substituent(s);
- (iv) an —R5—NH— group or an —NH—R5— group, wherein R5 represents a C1-5 alkylene group optionally having a substituent(s), or a C2-5 alkenylene group optionally having a substituent(s);
- or
- (v) a secondary or tertiary amino group.
13 more elements
A method for preparing a pharmaceutical for the treatment of colon cancer, wherein said method comprises combining a pharmaceutically acceptable carrier and a therapeutic amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:
- wherein
- m represents an integer of 0 to 3, and n represents an integer of 0 to 2, with the proviso that 1<m+n<3;
- R1 represents a hydrogen atom, a hydrocarbon group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), or an amino group optionally having a substituent(s);
- R2 represents a polycyclic aryl group optionally having a substituent(s), a heterocyclic group optionally having a substituent(s), an aryloxy group optionally having a substituent(s), a phenyl group having a substituent(s), an aralkyl group having a substituent(s), or a group represented by the following Formula (II):
- wherein Ring A and Ring B each represent a monocyclic or polycyclic aryl group or heterocyclic group optionally having a substituent(s);
- R4 represents a single bond, a C1-3 alkylene group optionally having a substituent(s), a C2-3 alkenylene group optionally having a substituent(s), or a divalent oxy group;
- and the Ring A, Ring B, or R4 moiety is linked to X;
- R3 represents 0 to 7 substituent(s) linked to the naphthyl group, each of which substituent(s) is the same or different and has 1 to 10 atoms;
- and
- X represents:
- (i) a single bond;
- (ii) a C1-6 alkylene group optionally having a substituent(s);
- (iii) a C2-6 alkenylene group optionally having a substituent(s);
- (iv) an —R5—NH— group or an —NH—R5— group, wherein R5 represents a C1-5 alkylene group optionally having a substituent(s), or a C2-5 alkenylene group optionally having a substituent(s);
- or
- (v) a secondary or tertiary amino group.
13 more elements
Dependencies are inferred from the claim text.